What Is the Life Expectancy After a TACE Procedure?

Median overall survival after transarterial chemoembolization (TACE) for liver cancer typically falls in the range of roughly one to two years, though the spread around that number is enormous. Some patients live five years or more, while others survive less than a year, and the difference comes down to how well the liver is functioning before treatment, how advanced the cancer is, how the tumor responds to the procedure, and what treatments follow. Because so many variables shape the outcome, a single life-expectancy figure after TACE is almost meaningless without context about the individual patient.

What the Survival Numbers Actually Look Like

Studies report median survival after TACE anywhere from about eight months to over two years, depending on the population studied and the era of treatment. A prospective cohort study of patients treated for primary liver cancer found one-year survival of 72%, three-year survival of 28%, and four-year survival of just 12%.¹ A six-year follow-up study in Ethiopia reported a median overall survival of about 13 months, with the one-year survival rate at 58% and the two-year rate dropping to 24%.² These numbers reflect real-world populations that include patients across a range of disease severity.

One counterintuitive finding is that older patients don’t necessarily do worse. A study comparing elderly and younger patients with hepatocellular carcinoma (HCC) who received TACE found that both overall median survival (14 months versus about 8 months) and disease-specific survival were significantly higher in the elderly group.³ That likely reflects selection bias: older patients who are offered TACE tend to have better liver function and less aggressive tumors, because doctors are more cautious about treating frail elderly patients in the first place. Still, it’s reassuring for older patients who worry that age alone disqualifies them from good outcomes.

Liver Function Is the Single Biggest Factor

If there’s one thing that determines whether you get months or years out of TACE, it’s how healthy your liver is going into the procedure. The liver has to absorb the damage that TACE inflicts on the tumor and surrounding tissue, and a liver already struggling with cirrhosis recovers poorly. Research consistently shows that markers of liver health, including the albumin-bilirubin (ALBI) grade and Child-Pugh score, are among the strongest predictors of how long a patient will live after treatment.

A study examining TACE alone versus TACE combined with targeted and immune therapy found that patients with better baseline liver function (ALBI grade 1) who received combination treatment had a median survival of about 42 months, while those with worse liver function (ALBI grade 2) on the same combination survived a median of roughly 23 months.⁴ That’s nearly double the survival time just from having healthier liver function at the start.

The cause of underlying liver disease also matters. A study stratifying patients by etiology found that those whose liver cancer arose without hepatitis B or C infection (the so-called non-B, non-C group, often linked to alcohol-related liver disease or fatty liver disease) experienced faster liver-function deterioration and worse overall prognosis than patients whose cancer developed on a background of hepatitis B or C.⁵ The reasons are still being studied, but the pattern is consistent enough that the underlying cause of cirrhosis can shift expectations.

Risk Scoring and What Predicts a Good or Poor Outcome

Doctors have developed scoring systems to try to sort patients into risk groups before and after TACE. The SNACOR model, for example, stratifies patients into low-, intermediate-, and high-risk categories. In one validation study, the low-risk group had a median survival of nearly 50 months, the intermediate-risk group about 31 months, and the high-risk group around 12 months. Patients in the high-risk category faced roughly six times the death risk compared with the low-risk group.⁶ Researchers have also experimented with neural network models that attempt to outperform these scoring systems, and initial results suggest modest improvement, though the differences haven’t always reached statistical significance for the best existing scores.⁷

Tumor size, the number of tumors, and alpha-fetoprotein (AFP) levels at the time of treatment all feed into these predictions. A high baseline AFP level (above 200 ng/mL) has been linked to dramatically worse outcomes. One study found that patients with AFP below that threshold had a median survival of about 29 months, while those above it survived a median of just six months.⁸ Even among patients who achieve a complete response on imaging, those whose AFP remains elevated (above 20 ng/mL) have shorter progression-free and overall survival compared with patients whose AFP normalizes.⁹

Conventional TACE Versus Drug-Eluting Bead TACE

TACE comes in two main flavors. Conventional TACE (cTACE) involves injecting a chemotherapy drug mixed with an oily contrast agent directly into the artery feeding the tumor, then blocking that artery with tiny particles. Drug-eluting bead TACE (DEB-TACE) uses microspheres pre-loaded with chemotherapy that release the drug slowly at the tumor site. The theoretical advantage of DEB-TACE is a more controlled drug release and potentially fewer systemic side effects.

Whether DEB-TACE actually extends life compared to conventional TACE remains debated. A systematic review and meta-analysis found that DEB-TACE achieved a better tumor response rate and disease control, and had lower rates of severe complications, but did not show clear superiority in overall survival or 30-day mortality.¹⁰ A prospective cohort study in Chinese patients found DEB-TACE was associated with longer median overall survival (25 months versus 21 months) and longer progression-free survival, though on deeper statistical analysis, DEB-TACE was not an independent predictor of longer survival after adjusting for other factors.¹¹ The practical takeaway is that both methods work, and the choice often depends on local expertise and availability rather than a dramatic survival advantage of one over the other.¹²

How Doctors Know Whether TACE Worked

One of the most important moments in a TACE patient’s journey is the follow-up imaging scan, usually done one to three months after treatment. The tumor’s response on that scan is one of the strongest predictors of long-term survival. But not all methods of measuring response are equal. Standard tumor-measurement criteria designed for chemotherapy trials (which just look at whether the tumor shrank in size) correlate poorly with survival after TACE, because TACE kills tumor tissue without always shrinking the overall mass.

Modified criteria that look at the reduction in living, contrast-enhancing tumor tissue do a much better job. One study found that patients classified as responders using these modified criteria survived a median of about 41 months, compared with roughly 17 to 21 months for non-responders.¹³ Another study confirmed that early response on contrast-enhanced MRI using these modified criteria significantly predicted survival.¹⁴ The modified response criteria were also independently predictive of survival in patients receiving TACE combined with sorafenib, with responders showing roughly a 50% reduction in death risk.¹⁵

If you’re a patient or caregiver, the key piece of information here is that a good response on the first follow-up scan is one of the strongest signs you’ll do well. Ask your medical team specifically about the modified response criteria result, not just whether the tumor “looks smaller.”

When TACE Stops Working

TACE is often repeated multiple times over the course of treatment, but there’s a point at which doing more rounds stops helping and starts doing harm. The tumor may stop responding, or the liver may deteriorate too much to tolerate additional procedures. Recognizing this moment, sometimes called TACE refractoriness, is critical.

Two retrospective studies from Japan found that patients who switched from TACE to systemic drug therapy (sorafenib) once they became refractory to TACE had significantly longer survival than those who kept getting TACE. One study reported a median survival of about 25 months after switching, versus roughly 12 months for those who continued TACE. Liver function was also better preserved in the group that switched.¹⁶ A separate review reinforced the idea that timely conversion to systemic therapy at the point of TACE failure, rather than before or after, had the greatest impact on survival.¹⁷

The lesson for patients is straightforward: TACE is not a treatment you stay on indefinitely. Knowing when to move on is just as important as starting it in the first place.

Combining TACE with Immunotherapy and Targeted Drugs

The most active area of research right now involves adding immunotherapy and anti-angiogenic drugs to TACE. The hypothesis is that TACE releases tumor material that primes the immune system, and adding checkpoint inhibitors on top of that could amplify the immune response. A target trial emulation study found that combination therapy (TACE plus immunotherapy and anti-angiogenic agents) was associated with a median survival of about 33 months, compared with 23 months for TACE alone.¹⁸

A meta-analysis of phase III randomized trials, however, was more cautious: it found that adding immunotherapy and targeted agents to TACE did not yet show a statistically significant reduction in mortality risk, though the overall survival data were described as immature, meaning not enough patients had been followed long enough to draw a firm conclusion.¹⁹ The study looking at TACE combined with targeted and immune therapy stratified by baseline liver function did show benefits for patients with poorer liver function (ALBI grade 2), where combination therapy nearly doubled median survival compared with TACE alone (about 23 months versus 14 months).⁴ This is a space where the evidence is evolving quickly, and the standard of care may shift over the next few years as more trial data mature.

How TACE Compares with Other Treatments

TACE is typically offered to patients who cannot have surgery, but it’s worth understanding how it stacks up against other options. For patients with intermediate-stage HCC, surgical resection, when feasible, is associated with better survival. A propensity-matched study reported five-year survival rates of about 61% for surgery, 38% for TACE combined with radiofrequency ablation (RFA), and just 15% for TACE alone.²⁰ For solitary tumors in the 5–8 cm range that couldn’t be surgically removed, one study found that RFA achieved better short-term survival, though long-term results were comparable to TACE.²¹

Radioembolization using yttrium-90 microspheres (sometimes called TARE) is another competitor. A meta-analysis found that radioembolization was associated with significantly better overall survival and longer time to tumor progression compared with TACE.²² A phase II trial comparing yttrium-90 radioembolization to DEB-TACE reported a median survival of about 30 months with radioembolization versus roughly 16 months with DEB-TACE.²³ Not every study shows that gap, though. An earlier comparison found that despite a higher tumor burden in the radioembolization group, median survival was similar between the two approaches (about 18 months for TACE versus 16 months for radioembolization).²⁴ The conflicting data reflect different patient populations and study designs, but the trend suggests radioembolization deserves consideration, particularly when it’s available.

TACE as a Bridge to Liver Transplant

For some patients, TACE isn’t the endgame. It’s a way to keep the cancer in check while waiting for a liver transplant, and in that role it can be remarkably effective. As a bridging strategy, TACE has been associated with five-year post-transplant survival rates as high as 93%.²⁵ TACE can also be used to shrink tumors that initially exceed transplant eligibility criteria, a process called downstaging. One study found that about 55% of patients for whom downstaging was attempted were successfully brought within Milan criteria, and being downstaged significantly improved their chances of receiving a transplant.²⁶ For patients who are successfully downstaged and transplanted, post-transplant survival is generally comparable to patients who met the criteria from the start.

This changes the calculus entirely. If you’re a transplant candidate, the survival question after TACE is less about how long TACE itself buys you and more about whether it can hold the line until a new liver arrives.

Complications That Affect the Outlook

TACE is not gentle on the body. A common set of side effects called post-embolization syndrome (PES), which includes fever, abdominal pain, nausea, and elevated liver enzymes, occurs in roughly a third of patients. A study of 144 patients found that about 36% developed PES, and those patients had significantly worse outcomes: median survival of 16 months versus 25 months for those who did not develop the syndrome. After adjusting for other factors, patients with PES had twice the risk of death.²⁷ Whether PES itself drives the worse outcome or simply signals a more vulnerable patient is still unclear, but it’s a useful early warning sign.

Advanced and Complicated Cases

Patients with portal vein tumor thrombus, where the cancer invades the blood vessels feeding the liver, face a particularly challenging situation. These patients are sometimes treated with TACE combined with additional local therapies. One study examining TACE plus radioactive seed implantation in patients with hepatic arterioportal shunts reported a median survival of about 12 months overall, with those who had an effective response to the shunt treatment surviving a median of roughly 13 months versus 8 months for non-responders.²⁸

TACE is also used for liver metastases from other cancers, though the evidence is less robust than for primary liver cancer. For colorectal cancer that has spread to the liver, reported median survival after TACE varies widely, from about 9 to 62 months depending on the study and the patient population.²⁹ For neuroendocrine tumor metastases to the liver, DEB-TACE has shown the ability to control disease for a median of about 15 months.³⁰ These are different diseases with different biological behavior, so the survival expectations from primary HCC studies don’t transfer directly.

Frailty and Age in Older Patients

While calendar age alone doesn’t appear to hurt outcomes, frailty does. A study examining the impact of frailty on long-term prognosis after TACE in elderly patients found that frail patients (as measured by a standardized frailty index) had significantly shorter overall survival. The mechanisms are intuitive: frail patients recover more slowly from the procedure, have reduced capacity for liver regeneration, and show weakened immune surveillance, which may allow the cancer to recur faster over time.³¹ The distinction matters: an active 78-year-old with preserved liver function may do better than a sedentary 65-year-old with cirrhosis and multiple chronic conditions. Frailty assessment, rather than age cutoffs, is a better way to set expectations.